» Articles » PMID: 14696971

Multinucleated Osteoclast Formation in Vivo and in Vitro by P2X7 Receptor-deficient Mice

Overview
Publisher Begell House
Date 2003 Dec 31
PMID 14696971
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The P2X7 receptor is a member of the family of P2X purinergic receptors, which upon sustained activation forms large pores in the plasma membrane. In cells of hematopoietic origin, P2X7 receptor activation has been shown to lead to multiple downstream events, including cytokine release, cell permeabilization, and apoptosis. This receptor has also been implicated in the generation of multinucleated giant cells, polykaryons, and osteoclasts. We have recently demonstrated that a blockade of this receptor inhibits osteoclast formation in vitro; therefore, we examined mice deficient in the P2X7 receptor in the context of bone. These mice were healthy and displayed no overt skeletal problems. Furthermore, we were able to demonstrate their ability to form multinucleated cells, in particular osteoclasts, both in vivo and in vitro. We also demonstrate the ability of P2X7R-/- multinucleated osteoclasts, upon stimulation with maitotoxin (MTX), to form pores in the plasma membrane in vitro. These findings are consistent with the existence of an endogenous pore structure present in osteoclast precursor cells that can be activated either by the P2X7 receptor, or in its absence, by alternative signals to mediate fusion and pore formation. These data provide further insight into the mode of action of the P2X7 receptor.

Citing Articles

Calcium-Permeable Channels Cooperation for Rheumatoid Arthritis: Therapeutic Opportunities.

Liang H, Yin H, Li S, Chen Y, Zhao Y, Hu W Biomolecules. 2022; 12(10).

PMID: 36291594 PMC: 9599458. DOI: 10.3390/biom12101383.


Extracellular ATP and its derivatives provide spatiotemporal guidance for bone adaptation to wide spectrum of physical forces.

Dsouza C, Moussa M, Mikolajewicz N, Komarova S Bone Rep. 2022; 17:101608.

PMID: 35992507 PMC: 9385560. DOI: 10.1016/j.bonr.2022.101608.


The P2RX7B splice variant modulates osteosarcoma cell behaviour and metastatic properties.

Tattersall L, Shah K, Lath D, Singh A, Down J, De Marchi E J Bone Oncol. 2022; 31:100398.

PMID: 35340569 PMC: 8948168. DOI: 10.1016/j.jbo.2021.100398.


P2X7 receptor knockdown suppresses osteoclast differentiation by inhibiting autophagy and Ca/calcineurin signaling.

Ma Y, Di R, Zhao H, Song R, Zou H, Liu Z Mol Med Rep. 2022; 25(5).

PMID: 35266012 PMC: 8941524. DOI: 10.3892/mmr.2022.12677.


Potential mechanisms of osteoprotegerin-induced damage to osteoclast adhesion structures via P2X7R-mediated MAPK signaling.

Ma Y, Shi X, Zhao H, Song R, Zou H, Zhu J Int J Mol Med. 2022; 49(5).

PMID: 35266010 PMC: 8920495. DOI: 10.3892/ijmm.2022.5115.